Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011407
Filing Date
2025-08-13
Accepted
2025-08-13 17:00:53
Documents
55
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q lvtx-20250630x10q.htm   iXBRL 10-Q 1168994
2 EX-31.1 lvtx-20250630xex31d1.htm EX-31.1 14411
3 EX-31.2 lvtx-20250630xex31d2.htm EX-31.2 14135
4 EX-32.1 lvtx-20250630xex32d1.htm EX-32.1 9208
5 EX-32.2 lvtx-20250630xex32d2.htm EX-32.2 8266
  Complete submission text file 0001558370-25-011407.txt   3897009

Data Files

Seq Description Document Type Size
6 EX-101.SCH lvtx-20250630.xsd EX-101.SCH 29598
7 EX-101.CAL lvtx-20250630_cal.xml EX-101.CAL 38086
8 EX-101.DEF lvtx-20250630_def.xml EX-101.DEF 73228
9 EX-101.LAB lvtx-20250630_lab.xml EX-101.LAB 236952
10 EX-101.PRE lvtx-20250630_pre.xml EX-101.PRE 181427
58 EXTRACTED XBRL INSTANCE DOCUMENT lvtx-20250630x10q_htm.xml XML 376642
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40241 | Film No.: 251212653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)